DE-102 (黃斑部水腫·黃斑部病變) :預測·市場分析 2023年
DE-102 (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 108 Pages
|DE-102 (黃斑部水腫·黃斑部病變) :預測·市場分析 2023年 DE-102 (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023|
|出版日期: 2014年10月31日||內容資訊: 英文 108 Pages||
參天製藥的開發平台候補藥──DE-102 (betamethasone) ，是治療糖尿病黃斑部水腫 (DME) 及視網膜分支靜脈阻塞症 (ME-BRVO) 用的steroid microsphere藥，目前日本正處於II/III實驗階段。betamethasone是糖皮質激素級的強力類固醇藥，同時具有抗發炎·免疫抑制性等雙方特徵。
本報告提供全球黃斑部水腫·黃斑部病變市場相關調查，提供您包含流行病學，病因，症狀，診斷，病理學，及治療指南的黃斑部水腫·黃斑部病變概要，以及包含競爭情形概要，產品說明，安全性，及功效簡介等的 DE-102 (betamethasone) 詳細資訊，並彙整主要國家的銷售額預測，日本的銷售額資訊等資料。
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Santen Pharmaceutical's pipeline candidate, DE-102 (betamethasone), is a steroid microsphere drug undergoing Phase II/III studies in Japan for the treatment of DME and ME-BRVO. Betamethasone is a potent steroid of the glucocorticoid class, with both anti-inflammatory and immunosuppressive properties. In preclinical studies, DE-102 demonstrated sustained efficacy when injected around the affected area, prompting Santen to develop the drug using a new delivery technology.